PE20231385A1 - Composiciones de vacunas multivalentes y usos de las mismas - Google Patents
Composiciones de vacunas multivalentes y usos de las mismasInfo
- Publication number
- PE20231385A1 PE20231385A1 PE2023001175A PE2023001175A PE20231385A1 PE 20231385 A1 PE20231385 A1 PE 20231385A1 PE 2023001175 A PE2023001175 A PE 2023001175A PE 2023001175 A PE2023001175 A PE 2023001175A PE 20231385 A1 PE20231385 A1 PE 20231385A1
- Authority
- PE
- Peru
- Prior art keywords
- antigen
- infections
- coli
- expec
- concentration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940031348 multivalent vaccine Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 150000004676 glycans Chemical class 0.000 abstract 4
- 229920001282 polysaccharide Polymers 0.000 abstract 4
- 239000005017 polysaccharide Substances 0.000 abstract 4
- 241000588724 Escherichia coli Species 0.000 abstract 3
- 208000019206 urinary tract infection Diseases 0.000 abstract 2
- 206010056519 Abdominal infection Diseases 0.000 abstract 1
- 206010007882 Cellulitis Diseases 0.000 abstract 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 abstract 1
- 206010058780 Meningitis neonatal Diseases 0.000 abstract 1
- 206010031252 Osteomyelitis Diseases 0.000 abstract 1
- 206010058674 Pelvic Infection Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 208000031650 Surgical Wound Infection Diseases 0.000 abstract 1
- 206010048038 Wound infection Diseases 0.000 abstract 1
- 230000003187 abdominal effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079734P | 2020-09-17 | 2020-09-17 | |
| EP21154782 | 2021-02-02 | ||
| US202163191471P | 2021-05-21 | 2021-05-21 | |
| PCT/IB2021/058485 WO2022058945A1 (en) | 2020-09-17 | 2021-09-17 | Multivalent vaccine compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231385A1 true PE20231385A1 (es) | 2023-09-12 |
Family
ID=77801756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001175A PE20231385A1 (es) | 2020-09-17 | 2021-09-17 | Composiciones de vacunas multivalentes y usos de las mismas |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12233118B2 (enExample) |
| EP (1) | EP4213870A1 (enExample) |
| JP (2) | JP7481585B2 (enExample) |
| KR (1) | KR20230043157A (enExample) |
| CN (3) | CN119454927A (enExample) |
| AU (1) | AU2021342797B2 (enExample) |
| BR (1) | BR112023004819A2 (enExample) |
| CA (1) | CA3190820C (enExample) |
| CL (1) | CL2023000740A1 (enExample) |
| CO (1) | CO2023002114A2 (enExample) |
| EC (1) | ECSP23019295A (enExample) |
| IL (2) | IL301248B2 (enExample) |
| JO (1) | JOP20230057A1 (enExample) |
| MX (1) | MX2023003169A (enExample) |
| PE (1) | PE20231385A1 (enExample) |
| PH (1) | PH12023550020A1 (enExample) |
| TW (1) | TW202227128A (enExample) |
| UY (1) | UY39428A (enExample) |
| WO (1) | WO2022058945A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL286467B2 (en) | 2019-03-18 | 2026-02-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them |
| CR20210522A (es) | 2019-03-18 | 2021-12-17 | Janssen Pharmaceuticals Inc | Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos |
| AR131046A1 (es) * | 2022-11-15 | 2025-02-12 | Janssen Pharmaceuticals Inc | Composiciones de vacunas multivalentes y sus usos |
| WO2024146325A1 (zh) * | 2023-01-06 | 2024-07-11 | 中国人民解放军军事科学院军事医学研究院 | 用于生产抗原多糖-载体蛋白生物偶联产物的工程菌及其应用 |
| GB202302579D0 (en) * | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2024186262A1 (en) * | 2023-03-03 | 2024-09-12 | Agency For Science, Technology And Research | Use of o-antigens for treating bacterial infections |
| EP4478050A1 (en) | 2023-06-12 | 2024-12-18 | Janssen Pharmaceuticals, Inc. | Method for quantifying bound acetate in glycoconjugates |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3700612A (en) | 1971-06-23 | 1972-10-24 | Tenneco Chem | Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422653D0 (en) | 1984-09-07 | 1984-10-10 | Technology Licence Co Ltd | Monoclonal antibodies |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
| EP0625910B1 (en) | 1992-02-11 | 2003-07-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Dual carrier immunogenic construct |
| DE69313134T2 (de) | 1992-06-25 | 1998-02-26 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| DK0616034T3 (da) | 1993-03-05 | 2005-02-21 | Wyeth Corp | Plasmid til fremstilling af CRM-protein og diphtheria toxin |
| EP0720485B1 (en) | 1993-09-22 | 2003-11-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
| AUPM399594A0 (en) | 1994-02-21 | 1994-03-17 | Csl Limited | Antigenic preparation for treatment or prevention of helicobacter infection |
| FI102976B (fi) | 1994-02-28 | 1999-03-31 | Valtion Teknillinen | Menetelmä lisäkeittokemikaalien tuottamiseksi sekä käyttämiseksi sulfa attiselluloosaprosessissa |
| DE69628418T2 (de) | 1995-03-22 | 2004-04-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| AU743114B2 (en) | 1997-04-01 | 2002-01-17 | Corixa Corporation | Aqueous immunologic adjuvant compositions of monophosphoryl lipid A |
| US6858211B1 (en) | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
| ES2284287T3 (es) | 1998-10-16 | 2007-11-01 | Glaxosmithkline Biologicals S.A. | Sistemas adyuvantes y vacunas. |
| WO2001078777A2 (en) | 2000-04-13 | 2001-10-25 | Mossman, Sally | Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21 |
| AU2001253568A1 (en) | 2000-04-18 | 2001-10-30 | Dan C. Deborde | Lipopolysaccharide-conjugate vaccine for sepsis treatment |
| RU2189253C1 (ru) | 2001-04-09 | 2002-09-20 | Государственный научный центр прикладной микробиологии | Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения |
| US6676958B2 (en) | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| DK1481057T3 (da) | 2002-03-07 | 2006-05-15 | Eidgenoess Tech Hochschule | System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært |
| AU2003901008A0 (en) | 2003-03-04 | 2003-03-20 | Anadis Ltd | Composition for the treatment and prevention of bacterial infections |
| CN1324134C (zh) | 2003-12-22 | 2007-07-04 | 南开大学 | 对大肠杆菌o81型的o－抗原特异的核苷酸 |
| AU2005229434B2 (en) | 2004-03-30 | 2010-09-30 | Nsgene A/S | Therapeutic use of a growth factor, NsG33 |
| ES2535084T3 (es) | 2005-05-11 | 2015-05-05 | Eth Zurich | Proteínas N-glicosiladas recombinantes procedentes de células procariotas |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| JP4791866B2 (ja) | 2006-03-24 | 2011-10-12 | 国立大学法人秋田大学 | 下痢原性大腸菌感染症の判別に用いられる固相等 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| WO2009036379A2 (en) | 2007-09-14 | 2009-03-19 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| CN102037004A (zh) | 2008-01-08 | 2011-04-27 | 生物种属学股份公司 | 使用寡糖基转移酶的多肽的糖缀合 |
| SI2257307T1 (sl) | 2008-02-20 | 2018-09-28 | Glaxosmithkline Biologicals S.A. | Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic |
| MX2011011376A (es) | 2009-04-27 | 2012-04-20 | Immuron Ltd | Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico. |
| CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| NO2501406T3 (enExample) | 2009-11-19 | 2018-05-19 | ||
| MX381912B (es) | 2010-07-16 | 2025-03-13 | Adimab Llc | Colecciones de anticuerpos. |
| US20130273098A1 (en) | 2010-12-10 | 2013-10-17 | Jeffrey T. Blue | Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions |
| CA2847621A1 (en) | 2011-09-06 | 2013-03-14 | Glycovaxyn Ag | Bioconjugate vaccines made in prokaryotic cells |
| US9932598B2 (en) | 2012-08-02 | 2018-04-03 | The Regents Of The University Of California | Metabolic engineering of microbial organisms |
| PT2885007T (pt) | 2012-08-16 | 2018-12-10 | Pfizer | Processos e composições de glicoconjugação |
| WO2014037585A1 (en) | 2012-09-10 | 2014-03-13 | Glycovaxyn Ag | Bioconjugates comprising modified antigens and uses thereof |
| KR20150068998A (ko) | 2012-10-12 | 2015-06-22 | 글리코박신 아게 | 숙주 세포 변형 방법 |
| EP2917351B1 (en) | 2012-11-07 | 2018-12-19 | GlaxoSmithKline Biologicals S.A. | Production of recombinant vaccine in e. coli by enzymatic conjugation |
| RU2672053C2 (ru) | 2012-12-20 | 2018-11-09 | Пфайзер Инк. | Способ гликоконъюгации |
| CA2896157A1 (en) | 2012-12-27 | 2014-07-03 | Glycovaxyn Ag | Methods and compositions relating to crm197 |
| HUE038915T2 (hu) | 2013-01-17 | 2018-12-28 | Arsanis Biosciences Gmbh | MDR E. colira fajlagos antitest |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| CN103495161B (zh) | 2013-10-08 | 2019-06-18 | 江苏康泰生物医学技术有限公司 | 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法 |
| BR112016007727A8 (pt) | 2013-10-11 | 2018-01-30 | Glycovaxyn Ag | célula hospedeira, e, método para produzir uma proteína n-glicosilada. |
| EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
| CN106163550A (zh) | 2013-12-04 | 2016-11-23 | 格林考瓦因有限公司 | 通过大肠杆菌中合成的糖蛋白疫苗预防金黄色葡萄球菌感染 |
| KR102301188B1 (ko) | 2014-02-06 | 2021-09-13 | 엑스4 파마슈티컬스 (오스트리아) 게엠베하 | 이. 콜라이 특이성 항체 서열 |
| NZ723328A (en) | 2014-02-24 | 2018-01-26 | Glycovaxyn Ag | Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture |
| MX378857B (es) | 2014-04-17 | 2025-03-10 | Glaxosmithkline Biologicals Sa | Celulas huespedes modificadas y usos de las mismas. |
| CN105695497B (zh) | 2014-11-27 | 2019-09-24 | 中国人民解放军军事医学科学院生物工程研究所 | 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用 |
| SI3240895T1 (sl) | 2014-12-30 | 2022-04-29 | Glaxosmithkline Biologicals S.A. | Sestavki in postopki za glikozilacijo proteinov |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| GB201711635D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| US11260119B2 (en) * | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| JP7551618B2 (ja) | 2018-12-12 | 2024-09-17 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｏ－結合型グリコシル化のための修飾キャリアタンパク質 |
| CR20210522A (es) * | 2019-03-18 | 2021-12-17 | Janssen Pharmaceuticals Inc | Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos |
| IL286467B2 (en) | 2019-03-18 | 2026-02-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them |
| FR3098334B1 (fr) | 2019-07-05 | 2021-07-23 | Airbus Operations Sas | Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef |
| MX2023011697A (es) * | 2021-04-01 | 2023-10-19 | Janssen Pharmaceuticals Inc | Produccion de bioconjugados o18 de e. coli. |
-
2021
- 2021-09-17 PE PE2023001175A patent/PE20231385A1/es unknown
- 2021-09-17 AU AU2021342797A patent/AU2021342797B2/en active Active
- 2021-09-17 TW TW110135002A patent/TW202227128A/zh unknown
- 2021-09-17 IL IL301248A patent/IL301248B2/en unknown
- 2021-09-17 CN CN202411689646.5A patent/CN119454927A/zh active Pending
- 2021-09-17 MX MX2023003169A patent/MX2023003169A/es unknown
- 2021-09-17 EP EP21772844.3A patent/EP4213870A1/en active Pending
- 2021-09-17 IL IL308201A patent/IL308201A/en unknown
- 2021-09-17 US US17/478,584 patent/US12233118B2/en active Active
- 2021-09-17 JP JP2023517329A patent/JP7481585B2/ja active Active
- 2021-09-17 KR KR1020237006127A patent/KR20230043157A/ko not_active Ceased
- 2021-09-17 BR BR112023004819A patent/BR112023004819A2/pt unknown
- 2021-09-17 CN CN202411689651.6A patent/CN119454928A/zh active Pending
- 2021-09-17 CN CN202180049038.6A patent/CN115803087B/zh active Active
- 2021-09-17 WO PCT/IB2021/058485 patent/WO2022058945A1/en not_active Ceased
- 2021-09-17 UY UY0001039428A patent/UY39428A/es unknown
- 2021-09-17 CA CA3190820A patent/CA3190820C/en active Active
- 2021-09-17 PH PH1/2023/550020A patent/PH12023550020A1/en unknown
-
2023
- 2023-02-27 CO CONC2023/0002114A patent/CO2023002114A2/es unknown
- 2023-03-15 CL CL2023000740A patent/CL2023000740A1/es unknown
- 2023-03-16 JO JOJO/P/2023/0057A patent/JOP20230057A1/ar unknown
- 2023-03-17 EC ECSENADI202319295A patent/ECSP23019295A/es unknown
-
2024
- 2024-04-25 JP JP2024071024A patent/JP2024099716A/ja active Pending
-
2025
- 2025-01-16 US US19/025,061 patent/US20250222088A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021342797B2 (en) | 2024-02-08 |
| MX2023003169A (es) | 2023-03-27 |
| CA3190820C (en) | 2024-11-19 |
| CO2023002114A2 (es) | 2023-03-07 |
| CN115803087B (zh) | 2024-12-06 |
| IL301248A (en) | 2023-05-01 |
| IL308201A (en) | 2024-01-01 |
| ECSP23019295A (es) | 2023-04-28 |
| KR20230043157A (ko) | 2023-03-30 |
| IL301248B2 (en) | 2024-04-01 |
| UY39428A (es) | 2022-03-31 |
| JP7481585B2 (ja) | 2024-05-10 |
| CL2023000740A1 (es) | 2023-09-29 |
| JP2024099716A (ja) | 2024-07-25 |
| CN119454927A (zh) | 2025-02-18 |
| US12233118B2 (en) | 2025-02-25 |
| BR112023004819A2 (pt) | 2023-04-18 |
| TW202227128A (zh) | 2022-07-16 |
| CN119454928A (zh) | 2025-02-18 |
| US20250222088A1 (en) | 2025-07-10 |
| CA3190820A1 (en) | 2022-03-24 |
| EP4213870A1 (en) | 2023-07-26 |
| PH12023550020A1 (en) | 2024-03-11 |
| IL301248B1 (en) | 2023-12-01 |
| WO2022058945A1 (en) | 2022-03-24 |
| AU2021342797A1 (en) | 2023-02-16 |
| JOP20230057A1 (ar) | 2023-03-16 |
| CN115803087A (zh) | 2023-03-14 |
| US20220088165A1 (en) | 2022-03-24 |
| JP2023539943A (ja) | 2023-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hatz et al. | Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study | |
| Baumann et al. | Recombinant OprF–OprI as a vaccine against Pseudomonas aeruginosa infections | |
| JOP20200141B1 (ar) | تركيبات مشتملة على متقارنات بروتين عديد سكاريد المكورات العقدية الرئوية وطرق استخدامها | |
| Thomsen et al. | Anti-Pseudomonas aeruginosa IgY antibodies augment bacterial clearance in a murine pneumonia model | |
| AR100859A1 (es) | Polisacáridos y sus usos | |
| CO2019007982A2 (es) | Composiciones de neisseria meningitidis y métodos respectivos | |
| ECSP23019295A (es) | Composiciones de vacunas multivalentes y usos de las mismas | |
| MX2021007496A (es) | Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y sus metodos de uso. | |
| ES2495744T3 (es) | Glucanos con adyuvante | |
| CY1111916T1 (el) | Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος | |
| ES2828039T3 (es) | Vacunas conjugadas de salmonela | |
| Zeng et al. | A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli | |
| Yagnik et al. | Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model | |
| Ali et al. | Escherichia coli in broiler chickens in Egypt, its virulence traits and vaccination as an intervention strategy | |
| ES2537019T3 (es) | Sacáridos Vi conjugados | |
| Souci et al. | Intranasal inoculations of naked or PLGA-PEI nanovectored DNA vaccine induce systemic and mucosal antibodies in pigs: A feasibility study | |
| ES2695172T3 (es) | Vacuna porcina contra SRRP y Lawsonia intracellularis | |
| CN104998256A (zh) | 一种猪用三联灭活疫苗的制备方法 | |
| Mansouri et al. | Enhanced immunoprotection against Acinetobacter baumannii infection: Synergistic effects of Bap and BauA in a murine model | |
| PE20221442A1 (es) | Composiciones inmunogenicas contra enfermedades entericas y metodos para su preparacion | |
| AR123545A1 (es) | Composiciones de vacunas multivalentes y usos de las mismas | |
| BR112023002872A2 (pt) | Composição de vacina que induz uma resposta imune contra o vírus sars-cov-2, procedimento para obter as omvs, e, uso da composição de vacina | |
| Katseff et al. | PcrV in an intranasal adjuvanted tobacco mosaic virus conjugate vaccine mediates protection from Pseudomonas aeruginosa via an early Th1/Th17 skewed localized and systemic immune response. | |
| Espinosa-de los Monteros et al. | Reemplazo de serotipos de Streptococcus pneumoniae en niños con vacuna conjugada antineumocóccica 7V en México | |
| Abushahba et al. | Safe subunit green vaccines confer robust immunity and protection against mucosal Brucella infection in mice. Vaccines. 2023; 11: 546 |